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Abstract
Vaccines are designed primarily to protect vaccinated individuals against the target infection.  In addition to this direct effect of 
vaccination, vaccination may increase the level of population (or herd) immunity by increasing the proportion of the population 
who are immune from infection.  For infections that are transmitted from person-to-person, or for which humans are important 
reservoirs of the infectious agent, an increase in the level of herd immunity may result in a lower force of infection in the 
population and thus a lower risk of infection among unvaccinated persons.   This is called an indirect effect of vaccination, or a 
herd-protective effect.  The effect of vaccination in increasing the level of herd immunity is important in disease elimination
programmes as, because of the indirect effect of vaccination on risk of infection, elimination may be achieved without having to
vaccinate the entire population.  An example is given of how the indirect effect of vaccination operates and the implications that 
this has for both disease control programmes and the interpretation of vaccine trials are discussed 
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1. Introduction  
For many infectious agents, the number of individuals in a population (herd) who are (relatively) immune to infection with an 
infectious agent depends on the proportion who have previously been infected with the infectious agent and the proportion of the
remainder who have been immunised with an efficacious vaccine against the agent.  A measure of the level of population-
immunity, or herd-immunity, is the proportion who are thus immune from further infection.  For many infections, the level of herd
immunity in a population may have an effect on the amount of transmission of the infection within the population and, in 
particular, may affect the risk of an uninfected becoming infected.  For such infections, increasing the level of herd immunity will 
decrease the risk of an uninfected person becoming infected [1-3]. 
For some infections this so-called herd effect, or herd protection, may be very important for disease control through vaccination.
If the herd effect reduces the risk of infection among the uninfected sufficiently, then the infection may no longer be sustainable
within the population and the infection may be eliminated.  This concept is important in disease elimination or eradication 
programmes.  It means, for example, that elimination of the infectious agent in a population can be achieved without necessarily
vaccinating the entire population. 
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Infections for which herd immunity may be important in affecting the risk of infection among non-immunes in the population are 
those infections which are transmitted directly from person to person (e.g. measles, rubella, varicella) or for which humans are the 
reservoir, or an important reservoir, of infection (e.g. polio, malaria).  There may be no herd protection the infection is not
generally transmitted from person to person and if humans are not an important reservoir of infection (e.g. tetanus, rabies). 
2. Infection in naïve populations and the basic reproduction number (R0)
Imagine a situation in which a person acquires an infection and then migrates to a population in which the infectious agent has
never previously circulated, and thus all in the population are susceptible to infection.  While the person is infectious and is
capable of transmitting the infectious agent to others, he or she will have contact with a number of other persons that is 
sufficiently “close” to infect them.  The number of persons thus infected will depend upon multiple factors, including the nature of 
the infectious agent and the contact patterns of the infectious person. However, it is possible to conceive of the average number of 
new transmissions of an infectious agent that will typically occur directly from an infectious person when he or she is newly 
introduced into the totally susceptible population.  This average number is known as the basic reproductive number and is 
commonly designated symbolically as “R0” - the average number of other persons that an infectious person will infect with an 
agent in a completely susceptible population. 
R0 will vary between different infectious agents depending on the infectiousness of the agent, which is influenced by factors such
as: how long it survives in the environment; the dose necessary for infection; the duration of infectiousness in the host, and 
whether or not infectiousness precedes infection symptoms.  R0 may also vary from population to population depending on factors 
such as population density, which may affect the number of effective contacts a person has while he/she is infectious.  It may also
vary with season for some infections, as the ambient conditions may affect the survival of the agent in the environment and the
extent to which people have close contact with each other may be different in warmer and colder periods. 
3. Infection in  populations  in which some are immune: indirect protection and the effective reproduction number (R) 
The indirect protection that may be provided to unvaccinated persons if the level of herd immunity is increased by vaccination is
illustrated schematically in Figure 1.  We consider an “idealised” population in which during the period of infectiousness an 
infectious person has contact with 4 other persons and with 2 of the 4 the contact is “close” enough for the infection to be 
transmitted.   
Figure 1: Idealised example illustrating the indirect protective effect of vaccination (herd-effect) when 50% of a naïve 
population is rendered immune by vaccination
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Thus in Figure 1(A), when the infectious person is introduced into a totally susceptible population, he or she infects 2 others (first 
generation) and then these 2 others each go on to infect a further 2 others of their 4 contacts (second generation).  In this situation 
the basic reproductive number (R0) is 2.
Now consider the same situation  after half of the population has been rendered  immune to infection by vaccination, so that (on average) 
2 out each person’s 4 contacts will be not-susceptible to infection.  When the initial infectious person is introduced into the population 
only one infection results (first generation) as one of the contacts who previously would have been infected has been protected by 
vaccination.  Similarly, the 1 newly infected person only goes on to infect 1 person (second generation) because half of the 
contacts have been directly protected by vaccination. In this situation the effective reproductive number (sometimes designated by 
“R”) is thus 1.  
Note the person circled in Figure 1(B).  This person was infected in the scenario considered in Figure 1(A) but was not infected 
in the scenario considered in Figure 1(B), even though the person had not been vaccinated. This is because the person was 
indirectly protected, as the person who would have infected them was themselves protected by vaccination and therefore did not 
pass the infection on. This is an illustration of a herd-protective effect of vaccination, where increasing the level of vaccination (in 
this case from zero to 50%) has reduced the risk of infection among the unvaccinated. Thus, in scenario (A) the attack rate among
susceptibles in the second generation was 25% whereas in scenario (B) it is 12.5% 
4. The herd immunity threshold 
In order for an infection which is transmitted from person to person, or for which humans are the principal reservoir, to be 
maintained in a population, each case of infection must give rise to at least one other case – i.e. the effective reproduction number 
must be above 1.  If  the effective reproduction number is below 1 then the infection will eventually die out in the population. That 
is, if the herd protective effect reduces the risk of infection among the uninfected sufficiently, then the infection will no longer be 
sustainable within the population and the infection will be eliminated.   
In general, the effective reproductive number (R) will be lower than the basic reproductive number (R0), depending on the 
proportion (P) of the population who are immune to infection.  Such immunity may be induced either by a previous infection with
the agent (if such infection produced immunity) and/or by immunisation with an effective vaccine.   Simply, R = (1-P) * R0.
Therefore, for infection elimination or eradication – i.e. to reduce R below 1, then P must be equal to at least (1-1/R0).  So, for 
example, if R0 = 5 then P must be at least (1-1/5) = 0.8.  That is, 80% of the population must be immune, either through previous 
infection or vaccination.
The value of P that reduces R to at most 1 is commonly called the “herd immunity threshold” – the level of population immunity 
that is necessary for the infection to be no longer self-sustaining in the population. 
Table 1 shows estimated values of R0 for some common infections and the derived values for the herd immunity thresholds using 
the formula given above.  The higher the value of R0 the higher the level of population immunity required (often achieved by 
increasing population coverage with a vaccine against the agent) for disease elimination.  The estimated value of R0 for pandemic  
Table 1.  Herd Immunity Thresholds (Approximate) for Infection Elimination
Infection Ro Herd immunity threshold 
Diphtheria 6-7 85%
Measles 12-18 83-94%
Mumps 4-7 75-86%
Pertussis 12-17 92-94%
Polio 5-7 80-86%
Rubella 6-7 83-85%
Smallpox 5-7 80-85%
Pandemic influenza (H1N1) 1.6? ~40% 
                             Taken, in part, from Fine[3]3
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influenza has varied in different studies but, usually, it appears to be low compared with other common infections and past 
pandemic influenza viruses.  If it is as low as 1.6, as indicated in Table 1, then once about 50% of a population have been infected 
or vaccinated  the infection may no longer show epidemic characteristics and will not be sustained in the population. It is 
important to stress that R0 may vary between different populations and in different segments, or at different times, in the same 
population, as discussed above.   Thus the required herd immunity threshold for infection elimination may be more complex to 
estimate that the simple formula given above. 
5. Infection elimination and eradication 
In common English the terms “elimination” and “eradication” are used interchangeably. However, in the parlance of disease 
control programmes they have come to have distinct definitions, as given below [4]: 
Elimination of infections: Reduction to zero of the incidence of infection caused by a specific agent in a defined geographical area 
as a result of deliberate efforts; continued measures to prevent re-establishment of transmission are required. Example: measles,
poliomyelitis. 
Eradication: Permanent reduction to zero of the worldwide incidence of infection caused by a specific agent as a result of 
deliberate efforts; intervention measures are no longer needed. Example: smallpox.  
6. Beneficial and deleterious effects of herd protection 
A major beneficial effect of increasing the level of population immunity through vaccination is that it may result in the elimination 
of the infectious agent from the population.  Even if the increase in population immunity is not sufficient to achieve infection
elimination (because, for example, the efficacy of the vaccine is poor or it is not possible to achieve sufficiently high vaccine
coverage), the risk of infection among unvaccinated person may still be reduced.  This may be particularly important for those for
whom vaccination is contraindicated (e.g. some live vaccines are not recommended for persons who are immunosuppressed).   
Also discussed in this context is the so-called “free-rider” paradox – that is, the “optimal” strategy for an individual with respect to 
vaccination in a population is that everybody else is vaccinated and the individual is not!  Thus, the individual is protected from 
infection because of the herd effect, but suffers none of the potential adverse effects of vaccination (which are observed for all
vaccines, albeit at a very low level for most). 
Although reducing the risk of infection among susceptible is generally a benefit, for some infections it may also result in 
deleterious effects.  For example, for common childhood infections, a consequence of reducing the risk of infection among 
susceptible is that for those who are infected the average age at infection will increase.  This may be of consequence when the
clinical consequences of infection are greater for those infected at older ages (e.g. polio, rubella, varicella, measles, and hepatitis 
A).
7. Measurement of direct and indirect effects of vaccination in controlled trials 
As discussed above, the indirect protective effect of a vaccine increases protection against infection even among the unvaccinated. 
Thus, the overall reduction in the incidence of infection in a population is greater than that which would be predicted just based on 
the direct protection that the vaccine gives to a vaccinated person. Controlled trials that are conducted before licensure of a
vaccine are generally designed to measure the individual protective effect of a vaccine whereas  herd effects are evaluated once
the vaccine has been introduced into public health programmes. The rationale for basing licensure of a vaccine on the individual
protective effect is based on several considerations.  First, demonstration of individual protection is critical, as only if the vaccine 
can be demonstrated to protect the individual will there be any possible herd effect.  Secondly, the individual protective effect of a 
vaccine is likely to be a property that is relatively invariant to the population in which the vaccine is being evaluated [1], whereas
the indirect effects of a vaccine will vary according to vaccine coverage in a population and may also vary from population to 
population, depending on the epidemiology of the infection in different environments.  Thirdly, in general, it is necessary to 
vaccinate larger numbers of people to demonstrate a herd effect compared to the number required to establish individual 
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protection, and some argue it is unethical to expose larger numbers of volunteers to an unlicensed product before individual 
protection is established. 
Nonetheless, for some vaccines the decision whether to use a licensed product in a public health programme may depend upon the 
magnitude of the herd effect, particularly if the vaccine is expensive.  Therefore, at some point, before or after licensure, studies to 
measure the magnitude of any herd effects may become a priority.  Such studies may be conducted after a vaccine has been 
introduced into a public health programme, and these are generally observational studies from which bias may be difficult to 
eliminate completely.  The possibility of conducting cluster randomised trials to evaluate both individual and herd protective 
effects has been advocated [5,6].  One possibility would be to randomise communities to either vaccine or control arms and the 
differences in the incidence of infection in vaccinated and unvaccinated communities would give a measure of the overall 
protective effect of vaccination, incorporating the summation of both direct and indirect effects. 
Another alternative, illustrated in Figure 2, would be to allocate some communities to receive no vaccine (control communities – 
Population 2 in Figure 2) and to randomise a proportion, say a half, of individuals in other communities to receive vaccine 
(Population 1 in Figure 2). By comparing the incidence of infection in different groups of persons, measures of both direct and 
indirect effects can be obtained.  First the direct protective effect of vaccination is obtained by comparing the incidence of 
infection among vaccinated and unvaccinated persons in Population 1: this is essentially the classic individually randomised 
controlled trial.  A measure of the indirect protective effect of vaccination can be obtained by comparing the incidence of infection 
among unvaccinated persons in Population 1 and those in Population 2, all of whom are unvaccinated.  A measure of the overall
protective effect of vaccination (combining both direct and direct effects) is obtained by comparing the incidence of infection among all 
persons in Population 1 with the incidence of infection among all persons in Population 2.   
Figure 2:  Measurement of direct and indirect effects of vaccination
Any herd effect of vaccination in Population 1 reduces the risk of infection of both vaccinated and unvaccinated persons in that
population.  Thus, a measure of what has been called the total protective effect of vaccination [6] among the vaccinated is provided by 
comparing the incidence of infection among the vaccinated in Population 1 with the incidence of infection among all those 
(unvaccinated) in Population 2. 
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Trials of this kind would be valuable to establish whether or not there was evidence of herd protective effects and to document the 
magnitude of these effects in a particular situation (in the example, with 50% vaccine coverage), but it is important to note that the 
magnitude of any herd effects is influenced critically by the proportion of the population that has been vaccinated. Thus it may be 
difficult to generalise from a trial of the kind outlined in estimating the magnitude of the herd protective effects when a vaccine is 
introduced in a public health programme.  
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